Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / BVXV - BiondVax gets supportive scientific advice for its COVID-19 therapy development plans

BVXV - BiondVax gets supportive scientific advice for its COVID-19 therapy development plans

BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals (NASDAQ:BVXV) on Tuesday said it got supportive scientific advice from Germany's Paul Ehrlich Institute (PEI) for its development plans for its COVID-19 therapy. PEI scientific advice is generally considered a first key step towards regulatory approval. PEI supports BVXV's plan for a combined phase 1/2a clinical trial in patients to test the safety and efficacy of its COVID-19 NanoAb therapeutic. "Generally, the PEI concurs with the proposed proof-of-concept study...and the overall nonclinical strategy that are required to support further clinical development as well as potential regulatory approval," minutes from the scientific advice meeting stated. BVXV's COVID-19 NanoAb is being developed as a patient friendly primary care product that may be self-administered through inhalation directly to the site of infection.

For further details see:

BiondVax gets supportive scientific advice for its COVID-19 therapy development plans
Stock Information
Company Name: BiondVax Pharmaceuticals Ltd.
Stock Symbol: BVXV
Market: NASDAQ
Menu
BVXV BVXV Quote BVXV Short BVXV News BVXV Articles BVXV Message Board
Get BVXV Alerts

News, Short Squeeze, Breakout and More Instantly...